Applying the concepts of financial options to stimulate vaccine development

Nature Reviews Drug Discovery

Volumn 5, Issue 8, 2006, Pages 641-647

  Brogan, David ^a   Mossialos, Elias ^a  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADVISORY COMMITTEE; ARTICLE; CONTINGENT VALUATION; DECISION MAKING; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; ECONOMIC ASPECT; FINANCIAL MANAGEMENT; FUNDING; GOVERNMENT REGULATION; HUMAN; INVESTMENT; MALARIA; PRIORITY JOURNAL; RESOURCE ALLOCATION; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; TUBERCULOSIS;

DRUG DESIGN; DRUG INDUSTRY; HUMANS; INVESTMENTS; RESEARCH; VACCINES;

EID: 33746634827     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2035     Document Type: Article

References (36)

1. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
2. Global Fund. Addressing HIV/AIDS, Malaria and Tuberculosis: The Resource Needs of the Global Fund, 2005-2007 [online], (2005).
3. International Finance Facility for Immunization (IFFIm). New international finance facility for immunisation could save 10 million lives. Press Release September 9 [online], (2005).
4. International Aids Vaccine Initiative. Incentives for Private Sector Development of an AIDS Vaccine Policy Brief #2 [online], (2004).
5. Mrazek, M. F. & Mossialos, E. Stimulating pharmaceutical research and development for neglected diseases. Health Policy 64, 75-88 (2003).
6. Kremer, M. in Innovation Policy and the Economy Vol.1 (eds Jaffe, A. B., Lerner, J. & Stern, S.) 35-72 (MIT Press, Cambridge 2001).
7. DiMasi, J. A. & Grabowski, H. G. Patents and R&D Incentives: Comments on the Hubbard and Love Trade Framework for Financing Pharmaceutical R&D. Submission to the Commission on Intellectual Property Rights, Innovation and Public Health 25 June 2004. [online], (2004).
8. Kremer, M. in Providing Global Public Goods: Managing Globalization (eds Kaul, I., Conceicao, P., Le Goulven, K. & Mendoza, R. U.) 502-503 (Oxford Univ. Press, 2003).
9. Webber, D. & Kremer, M. Stimulating industrial R&D for neglected infectious diseases: Economic perspectives. Bull. World Health Organization 79, 693-801 (2001).
10. Kremer, M. in Innovation Policy and the Economy Vol.1 (eds Jaffe, A. B., Lerner, J. & Stern, S.) 73-118 (MIT Press, Cambridge 2001).
11. Center for Global Development (CGD) (2005). Making Markets for Vaccines: Ideas to Action - The report of the Center for Global Development Advance Market Commitment Working Group [online], (2005).
12. Stewart, J. J., Allison, P. N. & Johnson, R. S. Putting a price on biotechnology. Nature Biotechnol. 19, 813-817 (2001).
13. Stewart, J. J. Biotechnology valuations for the 21st century. Milken Institute Policy Brief 27 [online], (2002).
14. Rogers, M., Gupta, A. & Maranas, C. D. Real options based analysis of optimal pharmaceutical research and development portfolios. Industrial Eng. Chem. Res. 41, 6607-6620 (2002).
15. Damodaran, A. The promise and peril of real options. Working Paper, Stern School of Business (1999).
16. Dixit, A., Pindyck, R. S. & Sodal, S. A markup interpretation of optimal investment rules. The Economic J. 109, 179-189 (1999).
17. Daum, J. How to create value with Real Options based innovation management. The New Economy Analyst Report [online], (2001).
18. Schwartz, E. S. Patents and R&D as real options. Economic Notes 33, 23-54 (2004).
19. Kellogg, D., Charnes, J. M. & Demirer, R. Valuation of a biotechnology firm: An application of real options methodologies. Proc. 3rd Annu. Intl Confer. on Real Options [online], (2000).
20. Rosati, N. Decision analysis and drug development portfolio management: uncovering the real options value of your projects. Expert Rev. Pharmaceoconomics Outcomes Res. 2, 179-187 (2002).
21. Trigeorgis, L. Real options and investment under uncertainty: What do we know? NBB Working Paper 22 [online], (2002).
22. Towse, A. & Kettler, H. Advance price or purchase commitments to create markets for treatments for diseases of poverty: Lessons from three policies. Bull. World Health Organization 83, 301-307 (2005).
23. Hsu, J. C. & Schwartz, E. S. A Model Of R&D valuation and the design of research incentives. NBER Working Paper 10041 [online], (2003).
24. Frost, L., Reich, M. & Fujisaki, T. Public Private Partnerships for Health 87-114 [online], (Harvard Univ. Press, Cambridge, 2002).
25. Barrett, D., Austin, J. & McCarthy, S. in Public Private Partnerships for Health 41-66 [online], (Harvard Univ. Press, Cambridge, 2002).
26. Bloom, B. R. & Widdus, R. Vaccine visions and their global impact. Nature Med. (Vaccine Suppl.) 4, 480-484 (1998).
27. Heady, C. Optimal taxation as a guide to tax policy: A survey. Fiscal Studies 14, 1-15 (1993).
28. Global Fund. The Framework Document of the Global Fund to Fight AIDS, Tuberculosis and Malaria [online], (2005).
29. Brugha, R. et al. The Global Fund: Managing great expectations. Lancet 364, 95-100 (2004).
30. Berenson, A. Big drug makers see sales decline with their image. New York Times 14 Nov 2005 [online], (2005).
31. Azar, A. Congressional Testimony before the Subcommittee on Health, Committee on Energy and Commerce, US House of Representatives. 6 April 2006.
32. Luehrman, T. A. What's it worth? A general manager's guide to valuation. Harvard Business Rev. 75, 132-142 (1997).
33. Jägle, A. J. Shareholder value, real options, and innovation in technology-intensive companies. R&D Management 29, 271-287 (1999).
34. Kremer, M. Pharmaceuticals and the Developing World. J. Economics Perspectives 16, 67-90 (2002).
35. Light, D. Making practical markets for vaccines. PLoS Med. 2, 934-938 (2005).
36. Struck, M. Vaccine R&D success rates and development times. Nature Biotechnol. 14, 591-593 (1996).